I
Inimex Pharmaceuticals
Innate Defense Regulator drugs for infections, tissue injury
About Inimex Pharmaceuticals
Inimex Pharmaceuticals was a clinical-stage biopharmaceutical company focused on developing a novel class of drugs called Innate Defense Regulators (IDRs) to combat infections and manage tissue injury. The company was founded in 2001 by Brett Finlay and R. Hancock, professors from the University of British Columbia, based on their research into immune system modulators. The firm's stated mission was the discovery, development, and commercialization of new medicines that selectively modulate the body's innate immune response.
The company's core technology centered on IDRs, which are small, synthetic peptides designed to trigger the body's innate defenses without causing harmful inflammation. Unlike traditional antibiotics that target bacteria directly, IDRs work by modulating host pathways, specifically by binding to the intracellular adaptor protein p62. This mechanism enhances the body's ability to clear a broad spectrum of pathogens, including antibiotic-resistant strains, and control inflammation, offering potential advantages where conventional antibiotics fail. The lead drug candidate, IMX942 (later SGX942), was developed to treat infections and conditions involving tissue injury, such as ventilator-associated pneumonia, cancer-related mucositis, and infections in chemotherapy patients.
Inimex successfully raised a total of $28 million over three funding rounds. A significant Series B financing round in June 2008 raised US$22 million, led by investors including Morningside Venture Investments, Roche Venture Fund, and Astellas Venture Management. This funding was crucial for advancing IMX942 into clinical trials. The first-in-human Phase 1 safety study of IMX942 began in April 2009. By 2010, the company had successfully completed Phase 1 studies and was planning Phase 2 trials. However, multiple sources indicate that Inimex Pharmaceuticals is now closed or archived.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Dec 2010 | $240K | — | State Small Business Credit Initiative | — |
| SERIES B✓Equity / VC | Jun 2008 | $22M | $88M | Astellas Venture · Morningside | — |
Growth signals
Inimex Pharmaceuticals's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
| Vancouver, Canada | Closed | — | $20M | $80M | |
Gyroscope TherapeuticsDeveloping one-time gene therapies for retinal diseases |
London, United Kingdom | Acquired | |||
Stayble TherapeuticsNew treatment for chronic back pain |
Göteborgs Stad, Sweden | Operational | |||
Cofactor GenomicsCofactor Genomics uses RNA to diagnose disease |
San Francisco, United States | Operational | |||
Bio Green Med SolutionClinical-stage biopharma developing cell cycle cancer therapies |
Berkeley Heights, United States | Operational | |||
Oxford ImmunotecProprietary T-cell based diagnostic tests for tuberculosis |
Milton, United Kingdom | Acquired | |||
OxagenSmall molecule drugs for inflammatory and respiratory diseases |
Milton, United Kingdom | Operational | |||
Janssen VaccinesVaccine development and manufacturing using proprietary platforms |
Leiden, Netherlands | Acquired |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Inimex Pharmaceuticals in the Burnaby ecosystem
The Inimex Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
State Small Business Credit Initiative
Series A4 investors entered at this stage
British Columbia Discovery Fund
GrowthWorks Capital
Morningside
Astellas Venture
Other known investors4 additional known investors
The University of British Columbia
BDC Capital
Canadian Medical Discoveries Fund- MCMDS Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Inimex Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Inimex Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








